PandemieGrippaleV1, PascalFrancis, Corpus, bibRecord, 000146

Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action

Identifieur interne : 000146 ( PascalFrancis/Corpus ); précédent : 000145; suivant : 000147

Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action

Auteurs : Charlotte I. S. Barker ; Matthew D. Snape

Source :

Lancet. Infectious diseases : (print) [ 1473-3099 ] ; 2014.

RBID : Pascal:14-0071052

Descripteurs français

Pascal (Inist)
- Narcolepsie, Immunoprophylaxie, Vaccin, Prévention, Surveillance, Grippe H1N1, Virus grippal A(H1N1).

English descriptors

KwdEn :
- H1N1 influenza, Immunoprophylaxis, Influenza A (H1N1), Narcolepsy, Prevention, Surveillance, Vaccine.

Abstract

The 2009 influenza A H1N1 pandemic placed unprecedented demand on public health authorities and the vaccine industry. Efforts were coordinated internationally to maximise the speed of vaccine development, distribution, and delivery, and the European Union's novel fast-track authorisation procedures mandated increased postmarketing surveillance to monitor vaccine safety. Clinicians in Finland and Sweden later identified an apparent increase in the incidence of narcolepsy associated with a specific adjuvanted pandemic influenza vaccine. After extensive review, the European Medicines Agency confirmed the existence of this association, which has since been detected in England, Ireland, France, and Norway. Assessments of the causal mechanisms continue. In this Review, we discuss how the narcolepsy association was detected, and we present the evidence according to the causality assessment criteria for adverse events following immunisation. The lessons learnt emphasise the central role of alert clinicians in reporting of suspected adverse reactions, and the importance of internationally robust postmarketing surveillance strategies as crucial components in future mass immunisation programmes.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 1473-3099`
A03		`1`		`@0 Lancet. Infect. dis. : (print)`
A05				`@2 14`
A06				`@2 3`
A08	`01`	`1`	`ENG`	`@1 Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action`
A11	`01`	`1`		`@1 BARKER (Charlotte I. S.)`
A11	`02`	`1`		`@1 SNAPE (Matthew D.)`
A14	`01`			`@1 Oxford Vaccine Group, Department of Paediatrics, Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford @2 Oxford @3 GBR @Z 1 aut. @Z 2 aut.`
A14	`02`			`@1 Oxford University Clinical Academic Graduate School, Medical Sciences Division, University of Oxford @2 Oxford @3 GBR @Z 1 aut.`
A14	`03`			`@1 NIHR Oxford Biomedical Centre @2 Oxford @3 GBR @Z 2 aut.`
A20				`@1 227-238`
A21				`@1 2014`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 27478 @5 354000505772130140`
A44				`@0 0000 @1 © 2014 INIST-CNRS. All rights reserved.`
A45				`@0 102 ref.`
A47	`01`	`1`		`@0 14-0071052`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Lancet. Infectious diseases : (print)`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 The 2009 influenza A H1N1 pandemic placed unprecedented demand on public health authorities and the vaccine industry. Efforts were coordinated internationally to maximise the speed of vaccine development, distribution, and delivery, and the European Union's novel fast-track authorisation procedures mandated increased postmarketing surveillance to monitor vaccine safety. Clinicians in Finland and Sweden later identified an apparent increase in the incidence of narcolepsy associated with a specific adjuvanted pandemic influenza vaccine. After extensive review, the European Medicines Agency confirmed the existence of this association, which has since been detected in England, Ireland, France, and Norway. Assessments of the causal mechanisms continue. In this Review, we discuss how the narcolepsy association was detected, and we present the evidence according to the causality assessment criteria for adverse events following immunisation. The lessons learnt emphasise the central role of alert clinicians in reporting of suspected adverse reactions, and the importance of internationally robust postmarketing surveillance strategies as crucial components in future mass immunisation programmes.
C02	`01`	`X`		`@0 002B05C02C`
C02	`02`	`X`		`@0 002B17A02`
C03	`01`	`X`	`FRE`	`@0 Narcolepsie @5 01`
C03	`01`	`X`	`ENG`	`@0 Narcolepsy @5 01`
C03	`01`	`X`	`SPA`	`@0 Narcolepsia @5 01`
C03	`02`	`X`	`FRE`	`@0 Immunoprophylaxie @5 04`
C03	`02`	`X`	`ENG`	`@0 Immunoprophylaxis @5 04`
C03	`02`	`X`	`SPA`	`@0 Inmunoprofilaxia @5 04`
C03	`03`	`X`	`FRE`	`@0 Vaccin @5 07`
C03	`03`	`X`	`ENG`	`@0 Vaccine @5 07`
C03	`03`	`X`	`SPA`	`@0 Vacuna @5 07`
C03	`04`	`X`	`FRE`	`@0 Prévention @5 08`
C03	`04`	`X`	`ENG`	`@0 Prevention @5 08`
C03	`04`	`X`	`SPA`	`@0 Prevención @5 08`
C03	`05`	`X`	`FRE`	`@0 Surveillance @5 09`
C03	`05`	`X`	`ENG`	`@0 Surveillance @5 09`
C03	`05`	`X`	`SPA`	`@0 Vigilancia @5 09`
C03	`06`	`X`	`FRE`	`@0 Grippe H1N1 @4 CD @5 96`
C03	`06`	`X`	`ENG`	`@0 H1N1 influenza @4 CD @5 96`
C03	`06`	`X`	`SPA`	`@0 Gripe H1N1 @4 CD @5 96`
C03	`07`	`X`	`FRE`	`@0 Virus grippal A(H1N1) @4 CD @5 97`
C03	`07`	`X`	`ENG`	`@0 Influenza A (H1N1) @4 CD @5 97`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'appareil respiratoire @5 37`
C07	`01`	`X`	`ENG`	`@0 Respiratory disease @5 37`
C07	`01`	`X`	`SPA`	`@0 Aparato respiratorio patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Virose @5 38`
C07	`02`	`X`	`ENG`	`@0 Viral disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Virosis @5 38`
C07	`03`	`X`	`FRE`	`@0 Infection`
C07	`03`	`X`	`ENG`	`@0 Infection`
C07	`03`	`X`	`SPA`	`@0 Infección`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 39`
C07	`04`	`X`	`ENG`	`@0 Nervous system diseases @5 39`
C07	`04`	`X`	`SPA`	`@0 Sistema nervioso patología @5 39`
C07	`05`	`X`	`FRE`	`@0 Trouble neurologique @5 40`
C07	`05`	`X`	`ENG`	`@0 Neurological disorder @5 40`
C07	`05`	`X`	`SPA`	`@0 Trastorno neurológico @5 40`
C07	`06`	`X`	`FRE`	`@0 Trouble du sommeil @5 41`
C07	`06`	`X`	`ENG`	`@0 Sleep disorder @5 41`
C07	`06`	`X`	`SPA`	`@0 Trastorno sueño @5 41`
N21				`@1 097`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 14-0071052 INIST
ET :	Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action
AU :	BARKER (Charlotte I. S.); SNAPE (Matthew D.)
AF :	Oxford Vaccine Group, Department of Paediatrics, Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford/Oxford/Royaume-Uni (1 aut., 2 aut.); Oxford University Clinical Academic Graduate School, Medical Sciences Division, University of Oxford/Oxford/Royaume-Uni (1 aut.); NIHR Oxford Biomedical Centre/Oxford/Royaume-Uni (2 aut.)
DT :	Publication en série; Niveau analytique
SO :	Lancet. Infectious diseases : (print); ISSN 1473-3099; Royaume-Uni; Da. 2014; Vol. 14; No. 3; Pp. 227-238; Bibl. 102 ref.
LA :	Anglais
EA :	The 2009 influenza A H1N1 pandemic placed unprecedented demand on public health authorities and the vaccine industry. Efforts were coordinated internationally to maximise the speed of vaccine development, distribution, and delivery, and the European Union's novel fast-track authorisation procedures mandated increased postmarketing surveillance to monitor vaccine safety. Clinicians in Finland and Sweden later identified an apparent increase in the incidence of narcolepsy associated with a specific adjuvanted pandemic influenza vaccine. After extensive review, the European Medicines Agency confirmed the existence of this association, which has since been detected in England, Ireland, France, and Norway. Assessments of the causal mechanisms continue. In this Review, we discuss how the narcolepsy association was detected, and we present the evidence according to the causality assessment criteria for adverse events following immunisation. The lessons learnt emphasise the central role of alert clinicians in reporting of suspected adverse reactions, and the importance of internationally robust postmarketing surveillance strategies as crucial components in future mass immunisation programmes.
CC :	002B05C02C; 002B17A02
FD :	Narcolepsie; Immunoprophylaxie; Vaccin; Prévention; Surveillance; Grippe H1N1; Virus grippal A(H1N1)
FG :	Pathologie de l'appareil respiratoire; Virose; Infection; Pathologie du système nerveux; Trouble neurologique; Trouble du sommeil
ED :	Narcolepsy; Immunoprophylaxis; Vaccine; Prevention; Surveillance; H1N1 influenza; Influenza A (H1N1)
EG :	Respiratory disease; Viral disease; Infection; Nervous system diseases; Neurological disorder; Sleep disorder
SD :	Narcolepsia; Inmunoprofilaxia; Vacuna; Prevención; Vigilancia; Gripe H1N1
LO :	INIST-27478.354000505772130140
ID :	14-0071052

Links to Exploration step

Pascal:14-0071052

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action</title>
<author><name sortKey="Barker, Charlotte I S" sort="Barker, Charlotte I S" uniqKey="Barker C" first="Charlotte I. S." last="Barker">Charlotte I. S. Barker</name>
<affiliation><inist:fA14 i1="01"><s1>Oxford Vaccine Group, Department of Paediatrics, Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford</s1>
<s2>Oxford</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Oxford University Clinical Academic Graduate School, Medical Sciences Division, University of Oxford</s1>
<s2>Oxford</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Snape, Matthew D" sort="Snape, Matthew D" uniqKey="Snape M" first="Matthew D." last="Snape">Matthew D. Snape</name>
<affiliation><inist:fA14 i1="01"><s1>Oxford Vaccine Group, Department of Paediatrics, Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford</s1>
<s2>Oxford</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>NIHR Oxford Biomedical Centre</s1>
<s2>Oxford</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0071052</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0071052 INIST</idno>
<idno type="RBID">Pascal:14-0071052</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000146</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action</title>
<author><name sortKey="Barker, Charlotte I S" sort="Barker, Charlotte I S" uniqKey="Barker C" first="Charlotte I. S." last="Barker">Charlotte I. S. Barker</name>
<affiliation><inist:fA14 i1="01"><s1>Oxford Vaccine Group, Department of Paediatrics, Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford</s1>
<s2>Oxford</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Oxford University Clinical Academic Graduate School, Medical Sciences Division, University of Oxford</s1>
<s2>Oxford</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Snape, Matthew D" sort="Snape, Matthew D" uniqKey="Snape M" first="Matthew D." last="Snape">Matthew D. Snape</name>
<affiliation><inist:fA14 i1="01"><s1>Oxford Vaccine Group, Department of Paediatrics, Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford</s1>
<s2>Oxford</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>NIHR Oxford Biomedical Centre</s1>
<s2>Oxford</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Lancet. Infectious diseases : (print)</title>
<title level="j" type="abbreviated">Lancet. Infect.  dis. : (print)</title>
<idno type="ISSN">1473-3099</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Lancet. Infectious diseases : (print)</title>
<title level="j" type="abbreviated">Lancet. Infect.  dis. : (print)</title>
<idno type="ISSN">1473-3099</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>H1N1 influenza</term>
<term>Immunoprophylaxis</term>
<term>Influenza A (H1N1)</term>
<term>Narcolepsy</term>
<term>Prevention</term>
<term>Surveillance</term>
<term>Vaccine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Narcolepsie</term>
<term>Immunoprophylaxie</term>
<term>Vaccin</term>
<term>Prévention</term>
<term>Surveillance</term>
<term>Grippe H1N1</term>
<term>Virus grippal A(H1N1)</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The 2009 influenza A H1N1 pandemic placed unprecedented demand on public health authorities and the vaccine industry. Efforts were coordinated internationally to maximise the speed of vaccine development, distribution, and delivery, and the European Union's novel fast-track authorisation procedures mandated increased postmarketing surveillance to monitor vaccine safety. Clinicians in Finland and Sweden later identified an apparent increase in the incidence of narcolepsy associated with a specific adjuvanted pandemic influenza vaccine. After extensive review, the European Medicines Agency confirmed the existence of this association, which has since been detected in England, Ireland, France, and Norway. Assessments of the causal mechanisms continue. In this Review, we discuss how the narcolepsy association was detected, and we present the evidence according to the causality assessment criteria for adverse events following immunisation. The lessons learnt emphasise the central role of alert clinicians in reporting of suspected adverse reactions, and the importance of internationally robust postmarketing surveillance strategies as crucial components in future mass immunisation programmes.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1473-3099</s0>
</fA01>
<fA03 i2="1"><s0>Lancet. Infect.  dis. : (print)</s0>
</fA03>
<fA05><s2>14</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>BARKER (Charlotte I. S.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>SNAPE (Matthew D.)</s1>
</fA11>
<fA14 i1="01"><s1>Oxford Vaccine Group, Department of Paediatrics, Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford</s1>
<s2>Oxford</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Oxford University Clinical Academic Graduate School, Medical Sciences Division, University of Oxford</s1>
<s2>Oxford</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>NIHR Oxford Biomedical Centre</s1>
<s2>Oxford</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA20><s1>227-238</s1>
</fA20>
<fA21><s1>2014</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>27478</s2>
<s5>354000505772130140</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2014 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>102 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>14-0071052</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Lancet. Infectious diseases : (print)</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The 2009 influenza A H1N1 pandemic placed unprecedented demand on public health authorities and the vaccine industry. Efforts were coordinated internationally to maximise the speed of vaccine development, distribution, and delivery, and the European Union's novel fast-track authorisation procedures mandated increased postmarketing surveillance to monitor vaccine safety. Clinicians in Finland and Sweden later identified an apparent increase in the incidence of narcolepsy associated with a specific adjuvanted pandemic influenza vaccine. After extensive review, the European Medicines Agency confirmed the existence of this association, which has since been detected in England, Ireland, France, and Norway. Assessments of the causal mechanisms continue. In this Review, we discuss how the narcolepsy association was detected, and we present the evidence according to the causality assessment criteria for adverse events following immunisation. The lessons learnt emphasise the central role of alert clinicians in reporting of suspected adverse reactions, and the importance of internationally robust postmarketing surveillance strategies as crucial components in future mass immunisation programmes.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B05C02C</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17A02</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Narcolepsie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Narcolepsy</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Narcolepsia</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Immunoprophylaxie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Immunoprophylaxis</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Inmunoprofilaxia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Vaccin</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Vaccine</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Vacuna</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Prévention</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Prevention</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Prevención</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Surveillance</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Surveillance</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Vigilancia</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Grippe H1N1</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>H1N1 influenza</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Gripe H1N1</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Virus grippal A(H1N1)</s0>
<s4>CD</s4>
<s5>97</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Influenza A (H1N1)</s0>
<s4>CD</s4>
<s5>97</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'appareil respiratoire</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Virose</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Viral disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Virosis</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Trouble du sommeil</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Sleep disorder</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Trastorno sueño</s0>
<s5>41</s5>
</fC07>
<fN21><s1>097</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 14-0071052 INIST</NO>
<ET>Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action</ET>
<AU>BARKER (Charlotte I. S.); SNAPE (Matthew D.)</AU>
<AF>Oxford Vaccine Group, Department of Paediatrics, Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford/Oxford/Royaume-Uni (1 aut., 2 aut.); Oxford University Clinical Academic Graduate School, Medical Sciences Division, University of Oxford/Oxford/Royaume-Uni (1 aut.); NIHR Oxford Biomedical Centre/Oxford/Royaume-Uni (2 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Lancet. Infectious diseases : (print); ISSN 1473-3099; Royaume-Uni; Da. 2014; Vol. 14; No. 3; Pp. 227-238; Bibl. 102 ref.</SO>
<LA>Anglais</LA>
<EA>The 2009 influenza A H1N1 pandemic placed unprecedented demand on public health authorities and the vaccine industry. Efforts were coordinated internationally to maximise the speed of vaccine development, distribution, and delivery, and the European Union's novel fast-track authorisation procedures mandated increased postmarketing surveillance to monitor vaccine safety. Clinicians in Finland and Sweden later identified an apparent increase in the incidence of narcolepsy associated with a specific adjuvanted pandemic influenza vaccine. After extensive review, the European Medicines Agency confirmed the existence of this association, which has since been detected in England, Ireland, France, and Norway. Assessments of the causal mechanisms continue. In this Review, we discuss how the narcolepsy association was detected, and we present the evidence according to the causality assessment criteria for adverse events following immunisation. The lessons learnt emphasise the central role of alert clinicians in reporting of suspected adverse reactions, and the importance of internationally robust postmarketing surveillance strategies as crucial components in future mass immunisation programmes.</EA>
<CC>002B05C02C; 002B17A02</CC>
<FD>Narcolepsie; Immunoprophylaxie; Vaccin; Prévention; Surveillance; Grippe H1N1; Virus grippal A(H1N1)</FD>
<FG>Pathologie de l'appareil respiratoire; Virose; Infection; Pathologie du   système nerveux; Trouble neurologique; Trouble du sommeil</FG>
<ED>Narcolepsy; Immunoprophylaxis; Vaccine; Prevention; Surveillance; H1N1 influenza; Influenza A (H1N1)</ED>
<EG>Respiratory disease; Viral disease; Infection; Nervous system diseases; Neurological disorder; Sleep disorder</EG>
<SD>Narcolepsia; Inmunoprofilaxia; Vacuna; Prevención; Vigilancia; Gripe H1N1</SD>
<LO>INIST-27478.354000505772130140</LO>
<ID>14-0071052</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000146 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000146 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:14-0071052
   |texte=   Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action
}}

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021

	Serveur d'exploration sur les pandémies grippales
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les pandémies grippales

Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action

Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri